STABILIZED DOSAGE FORM OF ETIDRONATE-CYTARABINE CONJUGATE AND ITS APPLICATION Russian patent published in 2018 - IPC A61K9/19 A61K31/7068 A61K31/663 A61K47/02 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to medicine and pharmaceutics and discloses an anticancer drug in the form of a stabilized dosage form, which is a lyophilizate for preparing a solution for parenteral administration and a method for preparation thereof, solution for parenteral administration and its application. Stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer which is magnesium chloride, in the molar ratio of stabilizer to conjugate from 1:1 to 20:1.

EFFECT: novel dosage form of the anticancer drug provides the hydrolytic and physical stability of the conjugate during long-term storage, as well as the stability of conjugate solutions for parenteral administration for their clinical application.

18 cl, 1 ex, 9 tbl, 4 dwg